HCW Biologics (NASDAQ:HCWB) just reported results for the fourth quarter of 2023.
- HCW Biologics reported earnings per share of -30 cents. This was below the analyst estimate for EPS of -14 cents.
- The company reported revenue of $560,360.
- This was 37.74% worse than the analyst estimate for revenue of $900,000.